AtheroGenics Inc. (AGIX) Reports Positive Clinical Trial Results for Type 2 Diabetes Treatment
Diabetes is a word we’re all familiar with, but many people don’t know the list of afflictions associated with the disease, which include blindness, heart disease, stroke, kidney failure, amputations and nerve damage. Approximately 221 million people around the world have been diagnosed with type 2 diabetes. AtheroGenics Inc. (Nasdaq: AGIX) is a pharmaceutical company focused on the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease. The company today announced top-line results from its ANDES phase 3 clinical trial of AGI-1067, the company’s lead antioxidant and anti-inflammatory drug candidate for the treatment of type 2 diabetes. According…